HER2 is a central biomarker for breast cancer treatment selection and also plays a part in other indications like gastric cancer. Reliable and precise assessment of the HER2 status is key to correct treatment selection. A high number of 2+ scored “equivocal” cases causes additional FISH testing, which results in higher costs and a delay in diagnosis.

Download our whitepaper to learn more about Visiopharm’s continuous scoring of the connectivity of the membranous HER2 staining. With excellent sensitivity and specificity in regards to FISH testing, our IVDR certified HER2 APP supports pathologists in determining the HER2 Score accurately. Learn how it also enables a finer segmentation of HER2 expression, which can be relevant for assay development of future treatment options.